Literature DB >> 18323172

[Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer].

Takahiro Hirayama1, Kazumasa Matsumoto, Toshiki Tsuboi, Tetuo Fujita, Takefumi Satoh, Masatsugu Iwamura, Teruaki Ao, Shiro Baba.   

Abstract

We report a very rare side effect, anaphylactoid purpula, after intravesical administration of bacillus Calmette-Guerin (BCG). A 83-year-old man presented with purpura located on his bilateral lower legs. He had received transurethral resections four times for superficial bladder tumors. Intravesical therapy using BCG was performed. During the treatment course, asymptomatic purpura was suddenly seen in the lower legs after the third administration. Lymphocyte stimulation test was highly positive for BCG. He was diagnosed with anaphylactoid purpura caused by BCG. Conservative treatment was selected because there were no concomitant diseases in other organs. There have been no signs of recurrence of tumors or purpura during the one-year follow-up. However, physicians need to be cautious of anaphylactoid purpura which could lead to severe diseases, such as renal failure, gastrointestinal dysfunction and systematic arthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18323172

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  5 in total

Review 1.  Urological Manifestations of Henoch-Schonlein Purpura: A Review.

Authors:  Amanda Dalpiaz; Richard Schwamb; Yimei Miao; Jacquelyn Gonka; Wayne Walzter; Sardar A Khan
Journal:  Curr Urol       Date:  2015-07-10

Review 2.  BCG: a vaccine with multiple faces.

Authors:  Marco Antonio Yamazaki-Nakashimada; Alberto Unzueta; Luisa Berenise Gámez-González; Napoleón González-Saldaña; Ricardo U Sorensen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

3.  Henoch Schönlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy.

Authors:  Hiroyuki Tsukada; Hiroshi Miyakawa
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

4.  Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.

Authors:  S Lukacs; B Tschobotko; N A Szabo; Andrew Symes
Journal:  Case Rep Urol       Date:  2013-06-17

Review 5.  Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer.

Authors:  Azharuddin Mohammed; Zubair Arastu
Journal:  BMC Urol       Date:  2017-12-06       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.